Trial record 1 of 1 for:
grifola
Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01200004 |
|
Recruitment Status :
Terminated
(Slow Accrual.)
First Posted : September 13, 2010
Last Update Posted : August 2, 2013
|
Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Yukiguni Maitake Company Ltd.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The goal of this clinical research study is to find the highest tolerable dose of the combination of Grifola frondosa extract, azacitidine, and lenalidomide that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Advanced Cancers | Drug: Azacitidine Drug: Lenalidomide Drug: Grifola Frondosa | Phase 1 |
Show Detailed Description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 1 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase I Study of Epigenetic Immunomodulation Through the Use of Azacitidine, Lenalidomide, and Grifola Frondosa in Patients With Advanced Malignancy |
| Study Start Date : | April 2012 |
| Actual Primary Completion Date : | July 2013 |
| Actual Study Completion Date : | July 2013 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Azacitidine + Lenalidomide
Azacitidine 75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle. Lenalidomide starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
|
Drug: Azacitidine
75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle.
Other Names:
Drug: Lenalidomide Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
Other Names:
|
|
Experimental: Azacitidine + Lenalidomide + Grifola Frondosa
Once Lenalidomide MTD identified in combination with azacitidine, Grifola frondosa added. Cycle 1, azacitidine on day 1, lenalidomide on day 2 and Grifola frondosa on day 3. Azacitidine daily for 5 days every 28 days while lenalidomide and Grifola frondosa on days 1-21 of subsequent cycles.
|
Drug: Azacitidine
75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle.
Other Names:
Drug: Lenalidomide Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
Other Names:
Drug: Grifola Frondosa 3 mg/kg by mouth twice a day on days 1 - 21 of a 28 day cycle. |
|
Experimental: Expansion Group A
Azacitidine + Lenalidomide MTD, then 2 weeks later Grifola frondosa
|
Drug: Lenalidomide
Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
Other Names:
|
|
Experimental: Expansion Group B
Azacitidine + Grifola Frondosa, then 2 weeks later Lenalidomide
|
Drug: Lenalidomide
Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
Other Names:
|
Primary Outcome Measures :
- Maximum Tolerated Dose (MTD) [ Time Frame: 4 weeks ]MTD defined by patient dose limiting toxicities (DLTs) that occur in the first cycle (4 weeks).
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 13 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed diagnosis of an advanced solid tumor refractory to standard treatment or for which no standard therapy is available.
- Patients must have ECOG performance status 2 or better (0-2).
- Patients must have normal organ and marrow function as defined: Absolute lymphocyte count > 1,000 /uL, Absolute neutrophil count > 1,500 /uL, Platelets > 75,000 /uL, Bilirubin </= 1.5 * ULN and AST and/or ALT </= 2.5 * the institutional upper limit of normal (ULN), </= 5 * ULN for patients with liver metastases, Serum creatinine within normal limits; if abnormal, then a calculated creatinine clearance >/= 50 mL/min
- Patients must be able to understand and be willing to sign an IRB-approved written informed consent document.
- Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mlU/mL within 10-14 days prior to and again within 24 hours of prescribing lenalidomide (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide.FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).
- Patients must be 18 years of age or older since the safety and dosages of these study drugs has not been demonstrated in the pediatric population. Exception: patients who are 13 years old or older and have more than 50 kg of body weight will be eligible after consultation with their pediatric attending.
- Life expectancy greater than 3 months based on the attending physician's discretion.
- All study participants must be registered in the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist.
Exclusion Criteria:
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (NYHA Class III or IV), unstable angina pectoris, symptomatic cardiac arrhythmia, active bleeding, active thrombosis, or psychiatric illness/social situations that would limit compliance with study requirements.
- History of stroke or transient ischemic attack within 6 months prior to study enrollment and significant vascular disease (e.g., aortic aneurysm, aortic dissection) and symptomatic peripheral vascular disease.
- History of allergic reactions to the study drugs or their analogs.
- Patients that have had any treatment specific for tumor control within 3 weeks of study drug treatment or: a. within 2 weeks if cytotoxic agents were given weekly b. within 6 weeks for nitrosoureas or mitomycin C c. within 4 half-lives for targeted agents with half lives and pharmacodynamic effects lasting less than 5 days (that includes, but is not limited to, erlotinib, sorafenib, sunitinib, bortezomib, and other similar agents) d. failed to recover from toxic effects of any therapy prior to study entry
- Concurrent known immunosuppressors.
- Inability to swallow oral medication.
- Pregnant or breastfeeding women.
- Concurrent enrollment on another research study.
- Known hepatitis B and C infection, HIV infection and autoimmune disorders.
- Subjects with known moderate or severe renal impairment will be excluded if creatinine clearance < 60 ml/min.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01200004
Locations
| United States, Texas | |
| UT MD Anderson Cancer Center | |
| Houston, Texas, United States, 77030 | |
Sponsors and Collaborators
M.D. Anderson Cancer Center
Yukiguni Maitake Company Ltd.
Investigators
| Principal Investigator: | Siqing Fu, MD, PHD | UT MD Anderson Cancer Center |
Additional Information:
| Responsible Party: | M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT01200004 History of Changes |
| Other Study ID Numbers: |
2010-0076 |
| First Posted: | September 13, 2010 Key Record Dates |
| Last Update Posted: | August 2, 2013 |
| Last Verified: | July 2013 |
Keywords provided by M.D. Anderson Cancer Center:
|
Advanced solid tumor Azacitidine Grifola frondosa Basidiomycete fungus Lenalidomide |
Additional relevant MeSH terms:
|
Lenalidomide Thalidomide Azacitidine Immunologic Factors Physiological Effects of Drugs Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Growth Inhibitors |
Antineoplastic Agents Immunosuppressive Agents Leprostatic Agents Anti-Bacterial Agents Anti-Infective Agents Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors |